-
Epignostix announces CMS release of a preliminary gapfill price for their proprietary CPT Code for the Epignostix CNS Tumor Methylation Classifier test
Heidelberg, Germany, May 6, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics, announces today that the Centers for Medicare & Medicaid Services (CMS) have released a preliminary Medicare reimbursement rate for the CPT® (Current Procedural Technology) code for the Company’s proprietary Epignostix CNS Tumor Methylation Classifier – a molecular test for precision diagnostics of […]
-
Epignostix launches CNS and sarcoma diagnostic tumor classifier applications
Heidelberg, Germany, January 22, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of their CNS and sarcoma tumor classifiers- marking a substantial milestone in driving market development for their flagship indication, CNS tumor classification, and expansion to additional applications. Combining epigenetics […]
-
Heidelberg Epignostix appoints Helge Lubenow as CEO
Heidelberg, Germany, July 16, 2024 – Heidelberg Epignostix, a deeptech start-up committed to precision cancer diagnostics today announces the appointment of Helge Lubenow as CEO. She will be succeeding founder David Jones in the role who will continue to support Heidelberg Epignostix as Chief Scientific Officer. Helge Lubenow has almost 25 […]
